Connect Biopharma Holdings Limited (CNTB)
NasdaqGM · USD · Healthcare · Biotechnology
$0.8302 (-2.20%) as of
Key statistics
- Market cap
- 52.28M
- Forward P/E
- -1.08
- EPS (TTM)
- -1.1900
- Dividend yield
- 0.00%
- 52-week range
- 0.7320 – 3.8200
- Revenue (TTM)
- 2.95M
- Profit margin
- 0.00%
- Analyst target
- $5.88
- Volume
- 61.48k
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA, United States
- Employees
- 64
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.